Patents by Inventor Nicolas GOURDIN

Nicolas GOURDIN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12202907
    Abstract: The present invention relates to antigen-binding compounds that inhibit the enzymatic activity of soluble human CD39. The invention also relates to cells producing such compounds; methods of making such compounds, and antibodies, fragments, variants, and derivatives thereof; pharmaceutical compositions comprising the same; methods of using the compounds to diagnose, treat or prevent diseases, e.g., cancer.
    Type: Grant
    Filed: June 30, 2022
    Date of Patent: January 21, 2025
    Assignees: Innate Pharma, Orega Biotech
    Inventors: Stéphanie Chanteux, Laurent Gauthier, Nicolas Gourdin, Carine Paturel, Ivan Perrot, Benjamin Rossi
  • Patent number: 12195555
    Abstract: The present disclosure relates to multifunctional binding proteins comprising a first and a second antigen binding domains (ABDs) and all or part of an immunoglobulin Fc region or variant thereof, wherein the first ABD binds specifically to human BCMA and the second ABD binds specifically to human NKp46 and wherein all or part of the immunoglobulin Fc region or variant thereof bind to a human Fc-? receptor. The disclosure also relates to methods for making said binding proteins, compositions thereof, and their uses, including the treatment or prevention of proliferative disorders, including multiple myeloma (MM).
    Type: Grant
    Filed: September 19, 2023
    Date of Patent: January 14, 2025
    Inventors: Nicolas Gourdin, Laurent Gauthier, Alexandre Tang, Marielle Chiron, Angela Virone-Oddos, Alessandro Masiero, Jochen Beninga, Ingo Focken, Sambasiva Rao, Yanfeng Zhou, Leila Sevigny
  • Publication number: 20240034816
    Abstract: The present disclosure relates to multifunctional binding proteins comprising a first and a second antigen binding domains (ABDs) and all or part of an immunoglobulin Fc region or variant thereof, wherein the first ABD binds specifically to human BCMA and the second ABD binds specifically to human NKp46 and wherein all or part of the immunoglobulin Fc region or variant thereof bind to a human Fc-? receptor. The disclosure also relates to methods for making said binding proteins, compositions thereof, and their uses, including the treatment or prevention of proliferative disorders, including multiple myeloma (MM).
    Type: Application
    Filed: September 19, 2023
    Publication date: February 1, 2024
    Inventors: Nicolas GOURDIN, Laurent GAUTHIER, Alexandre TANG, Marielle CHIRON, Angela VIRONE-ODDOS, Alessandro MASIERO, Jochen BENINGA, Ingo FOCKEN, Sambasiva RAO, Yanfeng ZHOU, Leila SEVIGNY
  • Publication number: 20230340143
    Abstract: The present invention relates to antigen-binding compounds that inhibit the enzymatic activity of soluble human CD39. The invention also relates to cells producing such compounds; methods of making such compounds, and antibodies, fragments, variants, and derivatives thereof; pharmaceutical compositions comprising the same; methods of using the compounds to diagnose, treat or prevent diseases, e.g., cancer.
    Type: Application
    Filed: February 13, 2023
    Publication date: October 26, 2023
    Inventors: Stéphanie Chanteux, Nicolas Gourdin, Carine Paturel, Ivan Perrot, Benjamin Rossi
  • Publication number: 20230099801
    Abstract: The present invention relates to methods of using compounds that inhibit the enzymatic activity of soluble human CD39 to treat cancer, including but not limited to the treatment of cancers characterized by CD73 expressing cells.
    Type: Application
    Filed: July 28, 2022
    Publication date: March 30, 2023
    Inventors: Stéphanie CHANTEUX, Nicolas GOURDIN, Carine PATUREL, Ivan PERROT, Benjamin ROSSI
  • Patent number: 11578136
    Abstract: The present invention relates to antigen-binding compounds that inhibit the enzymatic activity of soluble human CD39. The invention also relates to cells producing such compounds; methods of making such compounds, and antibodies, fragments, variants, and derivatives thereof; pharmaceutical compositions comprising the same; methods of using the compounds to diagnose, treat or prevent diseases, e.g., cancer.
    Type: Grant
    Filed: March 16, 2018
    Date of Patent: February 14, 2023
    Assignees: INNATE PHARMA, OREGA BIOTECH
    Inventors: Stéphanie Chanteux, Nicolas Gourdin, Carine Paturel, Ivan Perrot, Benjamin Rossi
  • Publication number: 20230025732
    Abstract: The present invention relates to antigen-binding compounds that inhibit the enzymatic activity of soluble human CD39. The invention also relates to cells producing such compounds; methods of making such compounds, and antibodies, fragments, variants, and derivatives thereof; pharmaceutical compositions comprising the same; methods of using the compounds to diagnose, treat or prevent diseases, e.g., cancer.
    Type: Application
    Filed: June 30, 2022
    Publication date: January 26, 2023
    Inventors: Stéphanie Chanteux, Laurent Gauthier, Nicolas Gourdin, Carine Paturel, Ivan Perrot, Benjamin Rossi
  • Patent number: 11377503
    Abstract: The present invention relates to antigen-binding compounds that inhibit the enzymatic activity of soluble human CD39. The invention also relates to cells producing such compounds; methods of making such compounds, and antibodies, fragments, variants, and derivatives thereof; pharmaceutical compositions comprising the same; methods of using the compounds to diagnose, treat or prevent diseases, e.g., cancer.
    Type: Grant
    Filed: June 17, 2019
    Date of Patent: July 5, 2022
    Assignee: INNATE PHARMA
    Inventors: Stéphanie Chanteux, Laurent Gauthier, Nicolas Gourdin, Carine Paturel, Ivan Perrot, Benjamin Rossi
  • Patent number: 11130817
    Abstract: Provided are antibodies that bind and inhibit CD73, are capable of increasing the proliferation of T cells in the presence of CD39-expressing B cells and ATP. The invention also relates to cells producing such compounds; methods of making such compounds, and antibodies, fragments, variants, and derivatives thereof; pharmaceutical compositions comprising the same; methods of using the compounds to diagnose, treat or prevent cancer.
    Type: Grant
    Filed: October 11, 2016
    Date of Patent: September 28, 2021
    Assignees: INNATE PHARMA, CENTRE LÉON BÉRARD
    Inventors: Christophe Caux, Laurent Gauthier, Nicolas Gourdin, Christine Menetrier-Caux, Carine Paturel, Ivan Perrot
  • Publication number: 20200232974
    Abstract: The invention discloses a method for selecting a human patient for CD73 antagonist therapy, preferably immunotherapy, comprising the step of determination in a patient's biological sample, that lymphocytes, preferably CD4+ T cells, express CD73, wherein, upon a determination that lymphocytes, preferably CD4+ T cells, express CD73 in patient's biological sample, the patient is declared sensitive to immunotherapy using an antagonist of CD73, preferably an anti-CD73 antibody. Combined therapy with immunotherapy against an inhibitory ICP and/or with a chemotherapeutic agent sensitive to MDR1 exclusion activity is proposed.
    Type: Application
    Filed: March 30, 2017
    Publication date: July 23, 2020
    Inventors: Christine MENETRIER-CAUX, Nicolas GOURDIN, Christophe CAUX, Selena VIGANO, Pedro ROMERO, Marion BOSSENEC
  • Publication number: 20200024357
    Abstract: The present invention relates to antigen-binding compounds that inhibit the enzymatic activity of soluble human CD39. The invention also relates to cells producing such compounds; methods of making such compounds, and antibodies, fragments, variants, and derivatives thereof; pharmaceutical compositions comprising the same; methods of using the compounds to diagnose, treat or prevent diseases, e.g., cancer.
    Type: Application
    Filed: June 17, 2019
    Publication date: January 23, 2020
    Inventors: Stéphanie Chanteux, Laurent Gauthier, Nicolas Gourdin, Carine Paturel, Ivan Perrot, Benjamin Rossi
  • Publication number: 20190389961
    Abstract: The present invention relates to antigen-binding compounds that inhibit the enzymatic activity of soluble human CD39. The invention also relates to cells producing such compounds; methods of making such compounds, and antibodies, fragments, variants, and derivatives thereof; pharmaceutical compositions comprising the same; methods of using the compounds to diagnose, treat or prevent diseases, e.g., cancer.
    Type: Application
    Filed: March 16, 2018
    Publication date: December 26, 2019
    Inventors: Stéphanie Chanteux, Nicolas Gourdin, Carine Paturel, Ivan Perrot, Benjamin Rossi
  • Publication number: 20190225703
    Abstract: Provided are antibodies that bind and inhibit CD73, are capable of increasing the proliferation of T cells in the presence of CD39-expressing B cells and ATP. The invention also relates to cells producing such compounds; methods of making such compounds, and antibodies, fragments, variants, and derivatives thereof; pharmaceutical compositions comprising the same; methods of using the compounds to diagnose, treat or prevent cancer.
    Type: Application
    Filed: October 11, 2016
    Publication date: July 25, 2019
    Inventors: CHRISTOPHE CAUX, LAURENT GAUTHIER, NICOLAS GOURDIN, CHRISTINE MENETRIER-CAUX, CARINE PATUREL, IVAN PERROT
  • Publication number: 20190218308
    Abstract: The present invention relates to methods of using compounds that inhibit the enzymatic activity of soluble human CD39 to treat cancer, including but not limited to the treatment of cancers characterized by CD73 expressing cells.
    Type: Application
    Filed: March 29, 2019
    Publication date: July 18, 2019
    Inventors: Stéphanie Chanteux, Nicolas Gourdin, Carine Paturel, Ivan Perrot, Benjamin Rossi
  • Publication number: 20190218304
    Abstract: The present invention relates to methods of using compounds that inhibit the enzymatic activity of soluble human CD39 in the treatment of cancer to potentiate the activity of an agent or treatment that induces the extracellular release of ATP from tumor cells and/or induces the death of tumor cells.
    Type: Application
    Filed: March 29, 2019
    Publication date: July 18, 2019
    Inventors: Stéphanie CHANTEUX, Nicolas GOURDIN, Carine PATUREL, Ivan PERROT, Benjamin ROSSI